Currently Viewing:
Newsroom
Currently Reading
Kazia Gains Orphan Designation for Investigational Glioblastoma Treatment
February 25, 2018 – Kelly Davio
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors
February 23, 2018 – Jaime Rosenberg
This Week in Managed Care: February 23, 2018
February 23, 2018
AJMC® in the Press, February 23, 2018
February 23, 2018 – AJMC Staff
Liquid Biopsy Can Predict Outcomes in Patients With Triple-Negative Breast Cancer, Researchers Say
February 22, 2018 – Jaime Rosenberg
ICER Report: Costs of Approved CAR T-Cell Therapies Aligned With Clinical Benefit
February 21, 2018 – Jaime Rosenberg
What We're Reading: Cost of Healthcare Bills; Albertsons Buying Rite Aid; Pediatric Cancer Therapies
February 21, 2018 – AJMC Staff
Second-Line Nilotinib May Enable Patients With CML to Achieve Treatment-Free Remission
February 21, 2018 – Laura Joszt
Cancer Survivors Manage Fatigue With Placebo Pills
February 19, 2018 – Kaitlynn Ely

Kazia Gains Orphan Designation for Investigational Glioblastoma Treatment

Kelly Davio
Kazia Therapeutics Limited, an oncology-focused biotechnology company, announced on Friday that it has received the FDA’s Orphan Drug Designation for its investigational drug, GDC-0084, for the treatment of glioblastoma multiforme, the most aggressive form of primary brain cancer.
Sydney, Australia–based Kazia Therapeutics Limited, an oncology-focused biotechnology company, announced on Friday that it has received the FDA’s Orphan Drug Designation (ODD) for its investigational drug, GDC-0084, for the treatment of glioblastoma multiforme, the most aggressive form of primary brain cancer. The ODD grants a special status to the drug and confers on Kazia privileges including tax credits for qualified clinical testing and a waived FDA prescription drug user fee.

Kazia’s CEO, James Garner, MA, MBA, MBBS, said in a statement, “We are very pleased to have successfully completed this important regulatory step in the development of GDC-0084. We share FDA’s recognition of the need for new treatments in this very challenging disease, and we believe that GDC-0084 has great promise as a potential new therapy. We anticipate an imminent start of the phase II clinical study, and look forward to working closely with the participating clinicians.”

Kazia says that it expects to undertake the phase 2 clinical trial beginning in March or April of 2018. Initial data are expected in early 2019.

Glioblastoma multiforme, which is characterized by grade 4 astrocytomas, has a 5-year survival rate of just 3%. Current therapies include surgery to remove as much of the tumor as possible, followed by radiotherapy and treatment with temozolomide. Even among optimally treated patients, survival averages 15 months.

GDC-0084, which Kazia licensed from Genentech in 2016, is an inhibitor of the phosphoinositide-3-kinase pathway, which Kazia says appears to be disordered in the majority of cases of glioblastoma multiforme. A phase 1 study1 of the drug in 47 patients suggested that the drug crosses the blood–brain barrier, with a uniform distribution throughout the brain. Of the evaluable patients, 26 (55.3%) had a best overall response of progressive disease and 19 (40.4%) had stable disease.

In addition to GDC-0084, Kazia is also in development with TRX-E-002-1, a third-generation benzopyran molecule with activity against cancer stem cells. This drug is being developed to treat ovarian cancer and is in a phase 1 clinical trial in Australia and the United States.

Reference

1. Wen PY, Cloughesy TF, Olivero A, et al. A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. Presented the 2016 ASCO Annual Meeting, June 4, 2016; Alexandria, Virginia. https://meetinglibrary.asco.org/record/125239/abstract.

 
Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up